Efficacy of a 7-day vonoprazan, sitafloxacin, and amoxicillin triple therapy as a fourth-line salvage regimen for refractory Helicobacter pylori infection
Abstract
BACKGROUND: Treatment failure of three standard regimens for Helicobacter pylori infections has increased and represents a significant challenge. The VAS regimen, consisting of vonoprazan, amoxicillin, and sitafloxacin, represents a promising treatment option, supported by its strong acid suppression and broad-spectrum antimicrobial activity. OBJECTIVES: To evaluate the efficacy and safety of the VAS regimen as the fourth-line regimen for refractory H. pylori infection. METHODS: This prospective single-arm study involved patients with H. pylori infection who had failed three standard regimens. Participants received VAS regimen; comprising vonoprazan 20 mg twice daily, amoxicillin 1000 mg twice daily, and sitafloxacin 100 mg twice daily for 7 days. Genotypic resistance was identified and CYP2C19 and CYP3A5 were studied. Eradication success was assessed using the 13C-urea breath test at 4-8 weeks post-therapy. RESULTS: Twenty patients (mean age 64.4 ± 8.6 years) were enrolled. The eradication rate was 70.0% (95% confidence interval (CI): 45.7–88.1) in the intention-to-treat analysis and 68.42% (95% CI: 43.5–87.4) in the per-protocol analysis. Notably, genotypic resistance demonstrated 93.9% and 85.7% of levofloxacin and clarithromycin resistance respectively. Mild adverse events were reported by three patients (15%), including loose stools, nausea, and bloating. Neither antibiotic resistance nor CYP2C19 and CYP3A5 rapid metabolizer status was associated with eradication…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.